PMID- 34966201
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 0857-1074 (Print)
IS  - 2308-118X (Electronic)
IS  - 0857-1074 (Linking)
VI  - 36
IP  - 2
DP  - 2021
TI  - The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 
      Diabetes treated with twice-daily Premixed Human Insulin.
PG  - 167-171
LID - 10.15605/jafes.036.02.11 [doi]
AB  - OBJECTIVE: To evaluate the effect of adding DPP4 inhibitor (DPP4-i) on glycemic 
      variability (GV) in patients with type 2 diabetes mellitus (T2DM) treated with 
      premixed human insulin (MHI). METHODOLOGY: We conducted a prospective study in 
      patients with T2DM on twice-daily MHI with or without metformin therapy. Blinded 
      continuous glucose monitoring was performed at baseline and following 6 weeks of 
      Vildagliptin therapy. RESULTS: Twelve patients with mean (SD) age of 55.8 (13.1) 
      years and duration of disease of 14.0 (6.6) years were recruited. The addition of 
      Vildagliptin significantly reduced GV indices (mmol/L): SD from 2.73 (IQR 
      2.12-3.66) to 2.11 (1.76-2.55), p=0.015; mean amplitude of glycemic excursions 
      (MAGE) 6.94(2.61) to 5.72 (1.87), p=0.018 and CV 34.05 (8.76) to 28.19 (5.36), 
      p=0.010. In addition, % time in range (3.9-10 mmol/l) improved from 61.17 (20.50) 
      to 79.67 (15.33)%, p=0.001; % time above range reduced from 32.92 (23.99) to 
      18.50 (15.62)%, p=0.016; with reduction in AUC for hyperglycemia from 1.24 (1.31) 
      to 0.47 (0.71) mmol/day, p=0.015. Hypoglycemic events were infrequent and the 
      reduction in time below range and AUC for hypoglycemia did not reach statistical 
      significance. CONCLUSION: The addition of DPP4-I to commonly prescribed 
      twice-daily MHI in patients with T2DM improves GV and warrants further 
      exploration.
CI  - (c) 2021 Journal of the ASEAN Federation of Endocrine Societies.
FAU - Tan, Florence Hui Sieng
AU  - Tan FHS
AD  - Endocrine Unit, Department of Medicine, Sarawak General Hospital, Malaysia.
FAU - Tong, Chin Voon
AU  - Tong CV
AD  - Department of Medicine, Hospital Melaka, Malaysia.
FAU - Tiong, Xun Ting
AU  - Tiong XT
AD  - Clinical Research Center, Sarawak General Hospital, Malaysia.
FAU - Lau, Bik Kui
AU  - Lau BK
AD  - Endocrine Unit, Department of Medicine, Sarawak General Hospital, Malaysia.
FAU - Kuan, Yueh Chien
AU  - Kuan YC
AD  - Endocrine Unit, Department of Medicine, Sarawak General Hospital, Malaysia.
FAU - Loh, Huai Heng
AU  - Loh HH
AD  - Faculty of Medicine and Health Sciences, University of Malaysia Sarawak (UNIMAS), 
      Malaysia.
FAU - Pillai, Saravanan A/L Vengadesa
AU  - Pillai SAV
AD  - Department of Medicine, Hospital Melaka, Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20210903
PL  - Philippines
TA  - J ASEAN Fed Endocr Soc
JT  - Journal of the ASEAN Federation of Endocrine Societies
JID - 8608483
PMC - PMC8666489
OTO - NOTNLM
OT  - continuous glucose monitoring
OT  - dipeptidyl peptidase 4 inhibitors
OT  - glycemic variability
OT  - premixed human insulin
OT  - type 2 diabetes mellitus
COIS- The authors declared no conflicts of interest.
EDAT- 2021/12/31 06:00
MHDA- 2021/12/31 06:01
PMCR- 2021/01/01
CRDT- 2021/12/30 05:36
PHST- 2021/02/28 00:00 [received]
PHST- 2021/07/26 00:00 [accepted]
PHST- 2021/12/30 05:36 [entrez]
PHST- 2021/12/31 06:00 [pubmed]
PHST- 2021/12/31 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - JAFES-36-2-167 [pii]
AID - 10.15605/jafes.036.02.11 [doi]
PST - ppublish
SO  - J ASEAN Fed Endocr Soc. 2021;36(2):167-171. doi: 10.15605/jafes.036.02.11. Epub 
      2021 Sep 3.